Compare Avient Corporation (AVNT) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avient Corporation vs Humana Inc — how do they compare? Avient Corporation trades at $45.02 (market cap $4.17B), while Humana Inc trades at $384.83 (market cap $44.77B). The key difference: Humana Inc is far larger — about 10.7× Avient Corporation's market cap, and Avient Corporation pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| AVNT | HUM | |
|---|---|---|
Market Cap | $4.17B | $44.77B |
Sector | Technology | Health |
52-Week High | $45.69 | $409.42 |
52-Week Low | $27.48 | $163.67 |
Enterprise Value | $5.62B | $52.12B |
Dividend Yield | 2.42% | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Avient (AVNT) trades at $44.80, down 1.86% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates solid fundamentals with Q2 2026 EPS of $0.96 beating expectations by $0.07, marking the third consecutive earnings beat. Revenue growth of 5.8% to $917 million in Q2 2026 and improved net income margin of 5.1% reflect operational strength. Analyst consensus remains positive with 60% buy ratings and a $49.00 price target representing 9.4% upside potential.
Avient presents a favorable investment case with consistent earnings outperformance and positive analyst sentiment. The stock offers dividend income with recent $0.28 quarterly payments. Key risks include potential margin pressure from input costs and market volatility. Technical indicators show near-term overbought conditions with RSI at 78.87, suggesting possible consolidation before further upside toward the $49 consensus target.
Humana (HUM) trades at $386.11, up 0.17% today, with a neutral technical outlook and mixed fundamentals. The stock shows strong revenue growth reaching $129.66B in 2025 but faces margin compression with net income margin declining to 0.88%. Recent Q2 2026 earnings beat expectations with EPS of $7.61 versus $7.27 expected, while management focuses on Medicare Advantage margin expansion and cost reductions.
Outlook remains cautiously optimistic with a consensus price target of $409.93 offering 6% upside potential. Key opportunities include Medicare Advantage growth and operational efficiency gains, while risks involve margin pressure, regulatory changes in healthcare, and competitive threats. Analyst sentiment leans neutral with 57% hold ratings amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
